UBS raises target for uniQure stock from USD 27 to USD 48

Published on 10/25/2026 at 12:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue rose to USD 5.84 million from USD 5.26 million. UBS targets uniQure stock at USD 48 after 48-month AMT-130 data on October 14, 2026.

Targets and operating figures

UBS set a USD 48.00 target for uniQure on October 14, 2026.
Second-quarter 2026 revenue rose to USD 5.84 million from USD 5.26 million.
uniQure submitted one BLA for AMT-130 on September 2, 2026.

QURE, NL0010696654, Illustration mit AI erstellt.

uniQure (ISIN NL0010696654) received a new analyst benchmark when Markets Insider reported on October 14, 2026, that UBS began coverage with a Buy rating and a USD 48.00 price target, up from USD 27.00. The call followed uniQure's September update on AMT-130, its Huntington's disease gene therapy.

Three dates define the setup

The recent sequence started on September 2, 2026, when uniQure announced submission of one Biologics License Application for AMT-130. On September 29, the company announced additional data from ongoing Phase I/II studies, including a 48-month analysis. The latest event came on October 14, when UBS set its USD 48.00 target after initiating coverage.

What does the target imply?

The target sits against a still demanding clinical debate. Markets Insider reported on October 5, 2026, that Barclays cut its rating from Overweight to Equal Weight and reduced its target from USD 60.00 to USD 28.00 after the 48-month data raised questions about the interpretability of the results.

Operating figures add a second contrast. For the second quarter of 2026, uniQure reported revenue of USD 5.84 million, compared with USD 5.26 million in the same period of 2025, while its GAAP net loss widened to USD 81.06 million from USD 37.72 million, according to the company's investor materials.

Market value sets the test

The finance picture remains tied to clinical execution. On October 23, 2026, the Nasdaq quote showed a last traded price of USD 22.43 at 4:00 p.m. EDT, a market capitalization of USD 1.6 billion and a 52-week range of USD 8.73 to USD 71.50. At USD 22.43, the stock stood 53.27 percent below the USD 48.00 UBS target set on October 14, 2026.

Nasdaq context and trading level

uniQure develops gene therapies for serious diseases, including AMT-130 for Huntington's disease and Hemgenix for hemophilia B. The company submitted the AMT-130 application on September 2, 2026, while the September 29 update supplied the clinical context behind the current analyst split.

On Nasdaq, uniQure last traded at USD 22.43 on October 23, 2026 at 4:00 p.m. EDT. The further course of trading is shown by the continuously updated real-time quote of uniQure stock.